Discontinue use at the 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Not to be administered other than IV/IM (eg, IA, intrathecal). Limited clinical experience w/ treatment >3 days. Discontinue use if there is deterioration in any organ system functions during treatment. Increased risk of CV & thrombotic adverse events when taken long-term; patients w/ known CV disease or risk factors may be at greater risk. Carefully consider patients w/ significant risk factors for CV events (eg, HTN, hyperlipidaemia, DM, smoking). CV revascularization procedures other than CABG. Patients w/ active or history of GI disease (eg, ulceration, bleeding or inflammatory conditions); or concomitantly using aspirin. Possible increased GI complications when co-administered w/ corticosteroids, SSRIs, other antiplatelet drugs, other NSAIDs or alcohol. Monitor for any serious skin reactions. Possible DRESS; generalised bullous fixed drug eruption. Severe hypotension. Increase risk of bleeding w/ oral anticoagulants. Monitor anticoagulant activity in patients receiving warfarin or similar agents particularly during the 1st few days after initiating treatment. New onset or worsening of pre-existing HTN; closely monitor BP during initiation of therapy. Patients w/ compromised cardiac function, pre-existing oedema or other predisposing conditions to or worsened by fluid retention including those taking diuretics or at risk of hypovolemia. Patients w/ dehydration; rehydrate patients prior to therapy. Use the lowest recommended dose of Dynastat when co-administered w/ fluconazole. Closely monitor renal function in patients w/ advanced renal disease. Closely monitor kidney function & initiate Dynastat at the lowest recommended dose in patients w/ severe renal impairment (CrCl <30 mL/min) or those who may be predisposed to fluid retention. Moderate hepatic impairment (Child-Pugh class B). Carefully monitor for evidence of the development of a more severe hepatic reaction while on therapy. May diminish utility of diagnostic signs (eg, fever in detecting infections). Avoid concomitant use w/ other non-specific NSAIDs. Patients who experience dizziness, vertigo or somnolence after treatment should refrain from driving or operating machines. Not recommended in women attempting to conceive. Pregnancy (1st & 2nd trimesters). Not recommended in childn <18 yr. Elderly.
Sign Out
